TRML - NASDAQ

Tourmaline Bio, Inc.

Tourmaline Bio, Inc.

TRML·NASDAQ

$47.98

+0.0000%
HealthcareBiotechnology

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$1.23B
EPS-2.8900
P/E Ratio-7.02
Earnings Date04/30/2026

No Revenue Data

TRML has not reported any revenue values in the available annual periods.

-73.21M
Net Income
74%
3Y+8098351.0%
5Y+303.0%
10Y+303.0%
-77.26M
Operating Cash Flow
175%
3Y+93.0%
5Y+338.0%
10Y+338.0%
Tourmaline Bio, Inc.

Tourmaline Bio, Inc. Profit Bridge

TRML · NASDAQ
Revenue0.00
Cost of Goods Sold (39.00K)
Gross Profit-39.00K
Operating Expenses (89.73M)
Operating Income-89.73M
Interest Expense (0.00)
Other Income/Expense16.52M
Pretax Income-73.21M
Income Tax (0.00)
Net Income-73.21M
Net Income
-73.21M

Profitability Analysis

Tourmaline Bio, Inc. Income Statement

TRML • NASDAQ

Tourmaline Bio, Inc. Income StatementDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
REVENUE
GROSS PROFIT
Cost of Revenue
(39K)
(33K)
(6K)
(623K)
(447K)
(379K)
Gross Profit
-39K
-33K
-6K
-623K
-447K
-379K
OPERATING INCOME
Operating Expenses
(89.7M)
(45.4M)
(19.7M)
(46.9M)
(22.2M)
(18M)
Selling, General & Administrative
(22.7M)
(13M)
(2.2M)
(692.0)
(7M)
(4.6M)
Research & Development
(67M)
(32.4M)
(17.5M)
(212.0)
(15.3M)
(13.4M)
Operating Income
-89.7M
-45.4M
-19.7M
-47.5M
-22.7M
-18.4M
PRE-TAX INCOME
Interest Expense
(0.0)
(0.0)
(0.0)
(326K)
(23K)
(0.0)
Net Interest Income
16.5M
3.3M
0.0
-326K
-23K
0.0
Other Expenses
(0.0)
(0.0)
(0.0)
(46.9M)
(0.0)
(0.0)
Total Other Income Expenses Net
16.5M
3.3M
0.0
-326K
-23K
223K
Income Before Tax
-73.2M
-42.1M
-19.7M
-47.8M
-22.7M
-18.2M
NET INCOME
Net Income
-73.2M
-42.1M
-19.7M
-904.0
-22.7M
-18.2M

SEC Filings

TRML - Filing history and reports

No SEC filings available for TRML

Related Guides

Blog Categories

Continue your TRML research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.